Stocks Health care NRXS

NYSE · Health care

Neuraxis, INC (NRXS)

Neuraxis, INC brought in $5.3M of revenue over the twelve months to June 30, 2026, up 65.2% from a year earlier. It posted a net loss of $7.7M. In fiscal 2025 capital spending exceeded operating cash flow by $6.5M. At June 30, 2026 it held $8.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

Watch NRXS in 60 seconds

Follow NRXS

Free, no password. An email when NRXS files with the SEC.

Key facts about Neuraxis, INC

Net worth

Neuraxis, INC has a market value (market cap) of $79.4M at the latest share price, and shareholders' equity of $6.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $3.6M (+32.9% year on year), with a net loss of $7.8M. Over the 12 months to June 30, 2026: revenue $5.3M, net loss $7.7M.

Cash flow

In fiscal 2025 operations used $6.4M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

What Neuraxis, INC does

Neuraxis, INC is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on NYSE under the ticker NRXS.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where NRXS ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Neuraxis, INC has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 19, 2026
   Executive or director change 8-K
2. August 11, 2026
   Quarterly report 10-Q · period to June 30, 2026Revenue rose 116% to $1.9M versus the same quarter last year; diluted EPS -$0.19 versus -$0.22.
3. August 3, 2026
   Passive stake changed SCHEDULE 13G/A
4. July 30, 2026
   Shelf registration to sell securities (amended) S-3/A
5. July 23, 2026
   Shelf registration to sell securities S-3
6. July 10, 2026
   Employee stock plan registration S-8
7. July 10, 2026
   Other event 8-K
8. June 12, 2026
   Shareholder vote results 8-K
9. May 12, 2026
   Quarterly report 10-Q · period to March 31, 2026Revenue rose 80% to $1.6M versus the same quarter last year; diluted EPS -$0.18 versus -$0.33.
10. May 1, 2026
    Passive stake changed SCHEDULE 13G/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 29, 2026. Insider transactions on SEC

Insider trades

What the people running Neuraxis, INC did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 7 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns NRXS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 32 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

9 insiders reported holding 3,278,845 shares in total, about $20.7M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about NRXS

What does Neuraxis, INC do?

Neuraxis, INC is a company in the Health care sector, listed on NYSE as NRXS. Its shares trade on NYSE under the ticker NRXS.

What is Neuraxis, INC's net worth?

Neuraxis, INC has a market value (market cap) of $79.4M at the latest share price, and shareholders' equity of $6.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Neuraxis, INC profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $7.7M on revenue of $5.3M.

How much revenue does Neuraxis, INC make?

Over the twelve months to June 30, 2026 Neuraxis, INC reported revenue of $5.3M. That is 65.2% more than a year earlier.

When did Neuraxis, INC last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 29, 2026.

Similar companies

Compare NRXS with

Compare NRXS with any company

Follow NRXS

Get an email when Neuraxis, INC files with the SEC: results, executive changes, material agreements and annual reports.

Follow NRXS

Free, no password. An email when NRXS files with the SEC.

Where the numbers come from

Financial figures are the values Neuraxis, INC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.